Adaptin Bio (APTN) Cash & Equivalents (2022 - 2026)

Adaptin Bio (APTN) has 5 years of Cash & Equivalents data on file, last reported at $301309.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 87.31% year-over-year to $301309.0; the trailing twelve-month figure through Mar 2026 stood at $301309.0 (down 87.31% YoY), and the FY2025 full-year result was $459174.0, up 1247.14% from the prior year.
• Cash & Equivalents retreated to $301309.0 in Q1 2026, from $459174.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.4 million in Q1 2025 to a low of $322.0 in Q3 2024.
• A 5-year average of $427849.7 and a median of $28930.5 in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 179741.3% in 2025 and tumbled 87.31% in 2026, its largest moves.
• Tracing APTN's Cash & Equivalents over 5 years: stood at $500.0 in 2022, then surged by 850.8% to $4754.0 in 2023, then soared by 616.98% to $34085.0 in 2024, then jumped by 1247.14% to $459174.0 in 2025, then sank by 34.38% to $301309.0 in 2026.
• Business Quant data shows APTN's Cash & Equivalents at $301309.0 in Q1 2026, $459174.0 in Q4 2025, and $579089.0 in Q3 2025.